161.27 0.00 (0.00%)
After hours: 4:54PM EDT
|Bid||160.54 x 500|
|Ask||174.90 x 300|
|Day's Range||161.01 - 165.44|
|52 Week Range||102.56 - 184.79|
|PE Ratio (TTM)||304.28|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Valeant's (VRX) stock has lost roughly 21% of its value in 2018 despite management's efforts for a turnaround after the turmoil in 2016.
GlaxoSmithKline (GSK) initiates a phase III study evaluating Benlysta in combination with Rituxanin adult patients with systemic lupus erythematosus.
Regeneron (REGN) announces encouraging top-line results from the phase III study evaluating Eylea injection in moderately severe to severe non-proliferative diabetic retinopathy.
Heron Therapeutics' (HRTX) pipeline candidate, HTX-011, meets primary endpoint in two pivotal phase III studies in bunionectomy and hernia repair.
Geron (GERN) misses earnings and sales estimates in Q4. However, revenues almost double year over year. Imetelstat remains in focus.
Alexion's (ALXN) shares gained 3.4% following positive results from a phase III study on its important candidate, ALXN1210, wherein it was compared to its lead drug Soliris.
Catalyst Pharma (CPRX) reports in-line fourth-quarter 2017 loss and is on track to resubmit its new drug application for Firdapse in the first quarter of 2018.
Arena (ARNA) reports narrower-than-expected Q4 loss. However, revenues decrease year over year. The company is likely to advance ralinepag in phase III study in the second half of 2018.
Shares of Solid Biosciences (SLDB) were hit after the FDA put a clinical hold on a phase III study of lead DMD candidate, SGT-001.
AbbVie (ABBV) and partner Neurocrine Biosciences announce that the second of the two pivotal phase III studies evaluating elagolix, met the primary endpoint for treating women with uterine fibroids.
Sarepta (SRPT) will file a rolling NDA for its second DMD drug, golodirsen. The submission is expected to be completed in late 2018.
Aradigm (ARDM) submits regulatory applications for its bronchiectasis candidate, Linhaliq, in the EU. A response from the EMA is awaited within 21 days to notify if the filing is complete.
Regeneron (REGN) & Sanofi's Praluent achieves the primary endpoint in the ODYSSEY OUTCOMES trial as the drug reduces the overall risk of MACE by 15%.
Pfizer's (PFE) Xeljanz received a unanimous vote from an FDA advisory committee to include the ulcerative colitis (UC) indication in its label .
Corcept (CORT) is currently working on developing Korlym for additional indications. It also remains focused at the development of its pipeline progress.
Ligand Pharmaceuticals' unique business model allows it to acquire technologies for license to other biotechs and pharmas.
Investors were on edge Thursday as Wall Street waited awaited President's Trump decision on steel and aluminum tariffs around 3:30 p.m. ET.
Conatus (CNAT) reports narrower-than-expected loss in Q4 while revenues marginally fall short of estimates. However, the top line shows a massive year-over-year increase.